# Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

> **NCT02727205** · PHASE1 · COMPLETED · sponsor: **Inflamax Research Incorporated** · enrollment: 260 (actual)

## Conditions studied

- Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch

## Interventions

- **DRUG:** Rotigotine Transdermal System

## Key facts

- **NCT ID:** NCT02727205
- **Lead sponsor:** Inflamax Research Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2016-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02727205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02727205, "Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02727205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*